Skip to main content
Top
Published in: Sleep and Breathing 4/2011

01-12-2011 | Original Article

Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing

Authors: Douglas L. Prisco, Anthony L. Sica, Arunabh Talwar, Mangala Narasimhan, Kennedy Omonuwa, Babak Hakimisefat, Sophy Dedopoulos, Nawid Shakir, Harly Greenberg

Published in: Sleep and Breathing | Issue 4/2011

Login to get access

Abstract

Purpose

We performed nocturnal polysomnography in patients with pulmonary hypertension (PH) of varying etiologies to determine the association of metrics describing sleep-disordered breathing (SDB) with measures of PH severity.

Methods

Consecutive patients referred for evaluation of dyspnea on exertion and elevated pulmonary arterial pressure >30 mmHg on echocardiography, who underwent right and left heart catheterization and polysomnography, were included. Patients were not pre-selected for symptoms of sleep-disordered breathing.

Results

Twenty-eight patients including 22 females and six males with a mean age of 55.2 ± 11.9 years were evaluated. Etiologies of PH were idiopathic (32%) and PH associated with other diseases (68%). Most were World Health Organization (WHO) Functional class II (39%) and III (39%). The group mean pulmonary arterial pressure (mPAP) was 40.9 ± 15.1 mmHg. Diurnal resting and exercise arterial oxygen saturations (SaO2) were 94.9 ± 3.7% and 88.3 ± 8.9%. The mean apnea–hypopnea index (AHI) was 11.4 ± 19.8/h; 50% of all patients had an AHI ≥ 5/h; 30.6 ± 36.0% of total sleep time was spent with SaO2 < 90% (T90%); 66% of subjects with an AHI ≥ 5/h of sleep reported snoring, and 60% noted daytime somnolence; however, only 29% had an Epworth Sleepiness Scale ≥10. Right atrial pressure and mPAP were significantly correlated with AHI and T90%. The best predictive model relating PH severity to metrics of SDB was a highly significant association (p = 0.005) between mPAP and a linear combination of AHI and T90%.

Conclusions

SDB comprised of obstructive apneas, hypopneas, and nocturnal hypoxemia is prevalent in PH and cannot be accurately predicted by sleep apnea signs and symptoms or diurnal rest and exercise SaO2. The association of AHI and T90% with mPAP suggests a potential relationship between the pathophysiology of sleep-disordered breathing and PH.
Literature
1.
2.
go back to reference Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K, Golish JA, Stoller JK (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104(9):1300–1306PubMedCrossRef Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K, Golish JA, Stoller JK (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104(9):1300–1306PubMedCrossRef
3.
go back to reference Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC (2001) Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest 120:894–899PubMedCrossRef Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC (2001) Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest 120:894–899PubMedCrossRef
4.
go back to reference Atwood CW Jr, McCroy D, Garcia JGN, Abman SH, Ahearn GS (2004) Pulmonary artery hypertension and sleep-disordered breathing. Chest 126(suppl 1):S72–S77CrossRef Atwood CW Jr, McCroy D, Garcia JGN, Abman SH, Ahearn GS (2004) Pulmonary artery hypertension and sleep-disordered breathing. Chest 126(suppl 1):S72–S77CrossRef
5.
go back to reference Minai OA, Pandya CM, Golish JA, Avecillas JF, McCarthy K, Marlow S, Arroliga AC (2007) Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension. Chest 131:109–117PubMedCrossRef Minai OA, Pandya CM, Golish JA, Avecillas JF, McCarthy K, Marlow S, Arroliga AC (2007) Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension. Chest 131:109–117PubMedCrossRef
6.
go back to reference Ulrich S, Fischler M, Speich R, Bloch KE (2008) Sleep-related breathing disorders in patients with pulmonary hypertension. Chest 133:1375–1380PubMedCrossRef Ulrich S, Fischler M, Speich R, Bloch KE (2008) Sleep-related breathing disorders in patients with pulmonary hypertension. Chest 133:1375–1380PubMedCrossRef
7.
go back to reference Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension. Chest 131:1917–1928PubMedCrossRef Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension. Chest 131:1917–1928PubMedCrossRef
8.
go back to reference American Thoracic Society (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117 American Thoracic Society (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117
9.
go back to reference Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:S40–S47CrossRef Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:S40–S47CrossRef
10.
go back to reference Iber C, Ancoli-Israel S, Chesson AL, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. American Academy of Sleep Medicine, Westchester, IL Iber C, Ancoli-Israel S, Chesson AL, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. American Academy of Sleep Medicine, Westchester, IL
11.
go back to reference Series ATS/ERS Task Force (2005) Standardisation of lung function testing. Numbers 2, 3, 4. Eur Respir J 26:319–338, 511–522; 720–735CrossRef Series ATS/ERS Task Force (2005) Standardisation of lung function testing. Numbers 2, 3, 4. Eur Respir J 26:319–338, 511–522; 720–735CrossRef
12.
go back to reference Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O’Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM (2009) Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 6(8):e1000132PubMedCrossRef Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O’Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM (2009) Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 6(8):e1000132PubMedCrossRef
13.
go back to reference Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. NEJM 328:1230–1235PubMedCrossRef Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. NEJM 328:1230–1235PubMedCrossRef
14.
go back to reference Podszus T, Greenberg H, Scharf SM (1994) Influence of sleep state and sleep disordered breathing on cardiovascular function. In: Saunders NA, Sullivan CE (eds) Sleep and breathing, 2nd edn. Marcel Dekker, New York, pp 257–299 Podszus T, Greenberg H, Scharf SM (1994) Influence of sleep state and sleep disordered breathing on cardiovascular function. In: Saunders NA, Sullivan CE (eds) Sleep and breathing, 2nd edn. Marcel Dekker, New York, pp 257–299
15.
go back to reference Ward JP, McMurtry IF (2009) Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 9:287–296PubMedCrossRef Ward JP, McMurtry IF (2009) Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 9:287–296PubMedCrossRef
16.
go back to reference Jeffery TK, Wanstall JC (2001) Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92(1):1–20PubMedCrossRef Jeffery TK, Wanstall JC (2001) Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92(1):1–20PubMedCrossRef
17.
18.
go back to reference Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D (2009) Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. Am Coll Cardiol 53(15):1309–1317CrossRef Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D (2009) Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. Am Coll Cardiol 53(15):1309–1317CrossRef
19.
go back to reference Gjroup PH, Sadauskiene L, Wessels K, Nyvad O, Strunge B, Pedersen EB (2007) Abnormally increased endothelin-1 in plasma during the night on obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens 20:44–52CrossRef Gjroup PH, Sadauskiene L, Wessels K, Nyvad O, Strunge B, Pedersen EB (2007) Abnormally increased endothelin-1 in plasma during the night on obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens 20:44–52CrossRef
20.
go back to reference Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 121:69–88PubMedCrossRef Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 121:69–88PubMedCrossRef
21.
go back to reference Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF (2006) Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343(2):591–596PubMedCrossRef Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF (2006) Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343(2):591–596PubMedCrossRef
22.
go back to reference Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF (2006) Activation of nuclear factor kappa B in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 10:43–50PubMedCrossRef Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF (2006) Activation of nuclear factor kappa B in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 10:43–50PubMedCrossRef
23.
go back to reference Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372–2379PubMedCrossRef Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372–2379PubMedCrossRef
Metadata
Title
Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing
Authors
Douglas L. Prisco
Anthony L. Sica
Arunabh Talwar
Mangala Narasimhan
Kennedy Omonuwa
Babak Hakimisefat
Sophy Dedopoulos
Nawid Shakir
Harly Greenberg
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 4/2011
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-010-0411-y

Other articles of this Issue 4/2011

Sleep and Breathing 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine